BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 1,091 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 1,091 shares of BioLife Solutions stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $27,275.00. Following the sale, the insider now directly owns 58,816 shares of the company’s stock, valued at $1,470,400. This trade represents a 1.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Price Performance

NASDAQ:BLFS traded down $1.21 during mid-day trading on Thursday, hitting $25.06. The company’s stock had a trading volume of 278,326 shares, compared to its average volume of 349,466. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04. The stock has a fifty day moving average of $26.64 and a 200-day moving average of $25.51.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the prior year, the firm earned ($0.21) earnings per share. As a group, equities analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

BLFS has been the topic of several recent research reports. Benchmark restated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, HC Wainwright increased their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.86.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions in the fourth quarter valued at approximately $26,000. Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions in the third quarter valued at approximately $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions in the fourth quarter valued at approximately $31,000. Quest Partners LLC bought a new position in BioLife Solutions in the third quarter valued at approximately $57,000. Finally, 1620 Investment Advisors Inc. boosted its stake in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.